EVALUATION, OPTION AND LICENSE AGREEMENTEvaluation, Option and License Agreement • March 6th, 2020 • Ayala Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
Certain information marked as [***] has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
EVALUATION, OPTION AND LICENSE AGREEMENTEvaluation, Option and License Agreement • April 26th, 2019 • IDEAYA Biosciences, Inc. • Pharmaceutical preparations • Manchester
AMENDMENT #1 TO EVALUATION, OPTION AND LICENSE AGREEMENTEvaluation, Option and License Agreement • April 26th, 2019 • IDEAYA Biosciences, Inc. • Pharmaceutical preparations
THIS AMENDMENT #1 TO EVALUATION, OPTION AND LICENSE AGREEMENT (“Amendment #1”) is made as of April 24th, 2019 (the “Amendment Effective Date”) by and between IDEAYA BIOSCIENCES, INC., a Delaware corporation, having a principal place of business at 7000 Shoreline Court, Suite 350, South San Francisco, California 94080 (“Company”), Cancer Research Technology Limited, a company registered in England & Wales under number 1626049 and located at the Angel Building, 407 St John Street, London EC1V 4AD, England (“CRT”), and The University of Manchester, a public research university located at Oxford Road, Manchester M13 9PL, England (“Manchester”) (with CRT and Manchester, collectively, “Institute”).
EVALUATION, OPTION AND LICENSE AGREEMENT between THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW and HEART TEST LABORATORIES Dated: Ref: UOF00l.02173Evaluation, Option and License Agreement • February 28th, 2022 • Heart Test Laboratories, Inc. • Orthopedic, prosthetic & surgical appliances & supplies
So, by way of example only, if in one year the total number of Products sold by the Company or its Sub-Licensees is 1,000, the royalty due under this Clause 8.2 shall be $110,000 for that year (i.e. 250 x $125 + 250 x $115 + 250 x $105 + 250 x $95).
AMENDMENT No. 2 TO EVALUATION, OPTION AND LICENSE AGREEMENTEvaluation, Option and License Agreement • March 24th, 2020 • IDEAYA Biosciences, Inc. • Pharmaceutical preparations
THIS AMENDMENT No. 2 TO EVALUATION, OPTION AND LICENSE AGREEMENT (“Amendment No.2”) is made as of March 3, 2020 (the “Amendment No.2 Effective Date”) by and between IDEAYA BIOSCIENCES, INC., a Delaware corporation, having a principal place of business at 7000 Shoreline Court, Suite 350, South San Francisco, California 94080 (“Company”), Cancer Research Technology Limited, a company registered in England & Wales under number 1626049 and located at the Angel Building, 407 St John Street, London EC1V 4AD, England (“CRT”), and The University of Manchester, a public research university located at Oxford Road, Manchester M13 9PL, England (“Manchester”) (with CRT and Manchester, collectively, “Institute”).
